
Codiak BioSciences CDAK
Quarterly report 2022-Q3
added 11-03-2022
Codiak BioSciences Total Assets 2011-2026 | CDAK
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Codiak BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 172 M | 151 M | 116 M | 97.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 172 M | 97.7 M | 134 M |
Quarterly Total Assets Codiak BioSciences
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 134 M | - | 150 M | 172 M | 159 M | 175 M | 191 M | 151 M | 151 M | 151 M | 151 M | 116 M | 116 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 191 M | 116 M | 152 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
6.95 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Exelixis
EXEL
|
2.84 B | $ 48.43 | 9.03 % | $ 13.2 B | ||
|
Fortress Biotech
FBIO
|
186 M | $ 2.56 | 3.96 % | $ 71.4 M | ||
|
Midatech Pharma plc
MTP
|
18.2 M | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
Galapagos NV
GLPG
|
3.41 B | $ 28.78 | 1.36 % | $ 2.69 B | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
151 M | - | 2.54 % | $ 160 B | ||
|
Genmab A/S
GMAB
|
21.1 B | $ 27.93 | 1.41 % | $ 17.2 B | ||
|
Genprex
GNPX
|
10.2 M | $ 0.9 | 2.02 % | $ 839 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Grifols, S.A.
GRFS
|
21.4 B | $ 8.41 | 1.69 % | $ 6.83 B | ||
|
Athira Pharma
ATHA
|
92.2 M | - | - | $ 269 M | ||
|
InflaRx N.V.
IFRX
|
55.2 M | $ 2.47 | 25.39 % | $ 152 M | ||
|
Ionis Pharmaceuticals
IONS
|
3.52 B | $ 76.96 | 2.27 % | $ 12.3 B | ||
|
Kamada Ltd.
KMDA
|
379 M | $ 8.3 | 1.1 % | $ 260 M | ||
|
BioNTech SE
BNTX
|
22 B | $ 95.07 | -0.45 % | $ 27.2 B | ||
|
Kymera Therapeutics
KYMR
|
1.74 B | $ 86.14 | 4.15 % | $ 7.28 B | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
78.8 M | - | - | $ 231 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
942 M | $ 229.83 | -1.06 % | $ 4.2 B | ||
|
INmune Bio
INMB
|
32.4 M | $ 1.52 | -1.3 % | $ 37.6 M | ||
|
Liquidia Corporation
LQDA
|
328 M | $ 41.84 | 4.26 % | $ 3.6 B | ||
|
Mirum Pharmaceuticals
MIRM
|
843 M | $ 107.42 | 1.52 % | $ 5.39 B | ||
|
ACADIA Pharmaceuticals
ACAD
|
1.19 B | $ 22.32 | -0.13 % | $ 3.7 B | ||
|
MannKind Corporation
MNKD
|
792 M | $ 3.68 | 28.5 % | $ 1.12 B | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Nanobiotix S.A.
NBTX
|
67.8 M | $ 42.28 | 21.6 % | $ 286 B | ||
|
Esperion Therapeutics
ESPR
|
466 M | $ 3.13 | 0.55 % | $ 651 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 3.47 | -8.44 % | $ 5.71 M | ||
|
Aeterna Zentaris
AEZS
|
21.4 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
113 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
Aptose Biosciences
APTO
|
10 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Allakos
ALLK
|
244 M | - | - | $ 28.6 M | ||
|
AlloVir
ALVR
|
122 M | - | 4.14 % | $ 49.1 M | ||
|
Arcutis Biotherapeutics
ARQT
|
433 M | $ 23.86 | 1.88 % | $ 3.04 B | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Puma Biotechnology
PBYI
|
216 M | $ 7.5 | 2.04 % | $ 375 M | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B |